ILC in chronic inflammation, cancer and targeting with biologicals. (August 2021)

• Record Type: Journal Article
• Authors: De Pasquale, Claudia; Campana, Stefania; Bonaccorsi, Irene; Carrega, Paolo; Ferlazzo, Guido
• Is Part Of: Molecular aspects of medicine. Volume 80(2021)
• Publication Date: 2021-08
• Subjects: Innate lymphoid cells -- Chronic inflammation -- Cancer -- Tertiary lymphoid structures -- Autoimmunee disease -- Biological therapeutics; Pathology, Molecular -- Periodicals; Medicine -- Periodicals; Biochemistry -- Periodicals; Medicine -- Periodicals; Molecular Biology -- Periodicals; Pathologie moléculaire -- Périodiques; Médecine -- Périodiques; Electronic journals; 612.015
• DOI: 10.1016/j.mam.2021.100963
• Languages: English
• ISSNs: 0098-2997

Abstract

Abstract: Since their discovery, Innate Lymphoid Cells (ILC) have emerged as important effector cells, serving multiple roles in maintaining tissue homeostasis and responding to tissue insults. As such, dysregulations of their function and distribution have been observed in a variety of immune-mediated diseases, suggesting a specific role for ILC in the pathophysiology of several disorders including chronic inflammation and cancer. Here, we provide an updated view on ILC biology dissecting their pathological or protective contribution in chronic inflammatory diseases such as multiple sclerosis, inflammatory bowel diseases, psoriasis, rheumatoid arthritis, asthma and COPD, atherosclerosis, also exploring ILC role in tumor surveillance and progression. Throughout the review, we will also highlight how the potential dual role of these cells for protective or pathogenic immunity in many inflammatory diseases makes them interesting targets for the development of novel therapeutic strategies, particularly promising.